Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 17/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131215 | 0.89 | PARP1 (0.54) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14026517 | 0.86 | PARP1 (0.53) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14026336 | 0.83 | PARP1 (0.51) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14026308 | 0.81 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14131017 | 0.79 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14026320 | 0.79 | PARP1 (0.69) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14026262 | 0.76 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14130948 | 0.76 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL14131284 | 0.76 | PARP1 (0.46) | PDE4APDE4BPDE4CPDE4DPARP1 | |
| SCHEMBL1251837 | 0.74 | PARP1 (0.62) | PDE4APDE4BPDE4CPDE4DPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | PDE4A 3567/4885PDE4B 3796/4885PDE4C 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.